Skip to content
  • About
  • Team
  • Investor Relations
  • Publications
  • News
  • Contact Us
Menu
  • About
  • Team
  • Investor Relations
  • Publications
  • News
  • Contact Us

Author: mineralystx

ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor

ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation

© 2023 Mineralys Therapeutics, LLC

Terms & Conditions  |  Privacy Policy
Twitter Linkedin